For some of these cancers, approval is based on companion diagnostic testing for the expression of PD‐L1 in either cancer cells (TC), immune cells (IC; mononuclear cells, excluding polymorphonuclear leukocytes), or both (eg combined positive score), depending on cancer types. Here, CD274 is linked to cancer.